MedTrace Logo

MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric?

NCT03299855 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2023-10-18

No results posted yet for this study

Summary

This study concerns elderly patients with cancer with onco-geriatric assessment.

This study propose to associate the collection of the results with the Mini-Cog and the CODEX with the passing of the MoCA and the MMS tests, as well as a neuropsychological assessment, in order to determine if the patients have cognitive impairments, to evaluate the sensitivity of these 4 screening tests in elderly patients seeking treatment for their cancer. The results of this study will make it possible, where appropriate, to adapt the practice in the context of oncogeriatric assessment.

Conditions

  • Neoplasms

Interventions

OTHER

Passation of neuropsychological test

Passation of MoCA and MMS tests associated with neuropsychological test

Sponsors & Collaborators

  • UCOG (Unite de coordination en Onco-Gériatrie)

    collaborator UNKNOWN

  • Centre Francois Baclesse

    lead OTHER

Principal Investigators

  • florence JOLY, prof · Centre François Baclesse

Study Design

Allocation
NA
Purpose
OTHER
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-13
Primary Completion
2023-10-13
Completion
2023-10-13

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03299855 on ClinicalTrials.gov